Research news – August 2024
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new type of treatment that ‘trains’ a patient’s own immune cells to seek out and kill cancer.
- Research
Category: Research
Unlocking the Mysteries of Blood Cancer
In the ever-evolving landscape of blood cancer research, the quest to combat blood cancer continues to push boundaries. The New Directions in Leukaemia Research (NDLR) event in Adelaide last month brought together leading minds in the field to discuss breakthroughs, challenges, and the future of leukaemia treatment. From cutting-edge advancements in therapies to the promise of personalised medicine, the conference, sponsored by the Leukaemia Foundation, shed light on the latest discoveries and strategies shaping the fight against leukaemia.
- Research
Improving treatment of blood cancers using targeted therapies
Advancing the effective use of targeted therapies for blood cancers while reducing side effects
Understanding why some Lymphomas are resistant to CAR-T therapy
Rare brain lymphoma needs more research and clinical trials
Access to clinical trials of novel treatments, including immune checkpoint inhibitors and CAR T-cell therapy, could be a game changer for these patients, according to Dr Colm Keane. He is a clinical haematologist at the Princess Alexandra Hospital in Brisbane and a brain lymphoma researcher at the University of Queensland's Frazer Institute.
- Clinical trials
- Research
Improving outcomes for cutaneous T-cell lymphoma and cutaneous graft-versus-host disease
Haematologist, Dr Jessica Elliott’s interest is researching T-cell mediated skin disorders, in particular, two clinically similar but biologically divergent conditions – cutaneous T-cell lymphomas (CTCL) (a subtype of skin lymphoma) and cutaneous graft-versus-host disease (GVHD).
- Research
Expert Series: Dr Sun Loo on measurable residual disease in remission and relapse
For Dr Sun Loo, being part of an innovative clinical trial is a perfect fit. It furthers research into her field of interest – measurable residual disease (MRD), and the blood cancer she is passionate about – acute myeloid leukaemia (AML).
- Interviews with experts
- Research
Expert Series: Professor Tenen on his lifelong search for a cure for cancer
Professor Daniel Tenen, who has devoted his research career to searching for a cure for cancer, has found an “ideal target”. It’s a gene called SALL4.
- Interviews with experts
- Research
Expert Series: Associate Professor Nada Hamad on the importance of clinical trials
When talking to her patients, clinical haematologist and researcher Associate Professor Nada Hamad always considers their eligibility for a clinical trial.
- Chronic lymphocytic leukaemia
- Interviews with experts
- Research
- Treatments and side-effects
